SOURCE: MorphoSys AG

November 22, 2010 09:18 ET

MorphoSys to Host R&D Days in London and New York

MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwire - November 22, 2010) - MorphoSys AG / MorphoSys to Host R&D Days in London and New York Processed and transmitted by Thomson Reuters.

The issuer is solely responsible for the content of this announcement.

Conference call and webcast of the meetings on November 25, 2010 at 09:30 GMT (London) and on November 29, 2010 at 12:00 ET (New York)

MorphoSys AG will host two R&D days in November to give an update on its partnered pipeline, proprietary portfolio and recent technology developments.

London, November 25, 2010, 09:30 GMT (10:30 CET)

Dial-in numbers for the Conference Call:

Germany: +49 (0) 89 24443 2975

For U.K. residents: +44 (0) 20 3003 2666

For U.S. residents: +1 212 999 6659

MorphoSys offers participants the opportunity to follow the presentation through a simultaneous slide presentation online at

A replay of the conference call will be available on following the live event.

New York, November 29, 2010, 12:00 ET (17:00 GMT, 18:00 CET)

MorphoSys offers participants the opportunity to follow the presentation through a simultaneous slide presentation online at Questions can be asked via the webcasting system.

A replay of the webcast will be available on following the live event.

+++For the on site events, please register now: MorphoSys's R&D Day 2010+++
                      London - Thursday, November 25, 2010
                      New York - Monday, November 29, 2010

About MorphoSys:

MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visit

HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®) and RapMAT(®) are registered trademarks of MorphoSys AG. arYla™ is a trademark of MorphoSys.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.


--- End of Message ---

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;

Conference Alert:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

Contact Information

  • For more information, please contact:

    MorphoSys AG
    Dr. Claudia Gutjahr-Loser
    Head of Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-122

    Mario Brkulj
    Senior Manager Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-454

    Jessica Kulpi
    Specialist Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-332

    Email Contact